"When it comes to patient care in the connected era, insights are everything," said Jack Phillips, president and CEO of Roche Diagnostics Corporation. "The idea of a connected lab begins with an integrated core lab with connected automation. But it also involves linking instruments to data lakes, laboratories to physicians, and high-medical-value tests to clinical insights to help improve the way physicians manage their patients."
The Roche booth (#4606) will feature a virtual reality experience that allows attendees to take a self-guided tour through three types of connected labs, which include Roche's chemistry, molecular and tissue staining platforms as well as automation:
- High throughput laboratory
- Rapid response laboratory
- Compact footprint laboratory
In addition to the virtual reality experience, the booth will feature a variety of recently introduced in-vitro diagnostics solutions in its chemistry, molecular, tissue and point-of-care diagnostics portfolios:
- cobas e 801 module – high-volume immunoassay platform that provides nearly twice the throughput on the same footprint as its predecessor.
- cobas c 513 analyzer—fully automated chemistry platform that raises the standard in HbA1c testing throughput.
- cobas 6800 system—fully automated, moderate-complexity platform that brings transformational efficiency gains to molecular diagnostics.
- cobas Connection Modules (CCM)—high-volume automation solution that provides connectivity across disciplines and third-party platforms.
- cobas Liat PCR system—point-of-care analyzer with CLIA-waived, real-time PCR tests for flu A/B, flu A/B + RSV and strep A that provide lab-quality results in 20 minutes or less.
- cobas m 511 integrated hematology analyzer—automated system that uses a standardized slide-making and staining process, digital multi-spectral imaging and advanced algorithms to optimize cell counting and classification. This product is not cleared or available for use in the U.S. A 510(k) submission is pending.
The booth also includes an "Innovations and Pipeline" area that offers a glimpse into diagnostics products that have not been submitted for FDA approval and are not yet available for sale in the U.S.
In addition, Roche is continuing its commitment to discussing critical industry issues by sponsoring two workshops in conjunction with the AACC 2017 annual meeting:
- Integrating Innovation: Paving the Way to TnT Gen 5 Adoption
Tuesday, August 1, 11:30 am – 12:30 pm, Exhibit Hall, Theatre 2
- Quality Management: Bringing Value to your Laboratory Operations
Wednesday, August 2, 11:30 am – 12:30 pm, Exhibit Hall, Theatre 2
More information about the workshops, as well as an overview of the Roche booth, is available at www.aacc.roche.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or usdiagnostics.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Mike Weist
Communications Business Partner
Roche Diagnostics Corporation
Indianapolis, Indiana USA
317.521.3112 office
317.371.0035 mobile
[email protected]
SOURCE Roche Diagnostics
Related Links
https://usdiagnostics.roche.com
Share this article